Lumida
/AVIR
⌘K
Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc

AVIR
$4.87USD↑+3.29%+0.16 today

MARKET CAP

389.7M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$3
$6

AI Summary

Stalk
TrimMedium

In a Stage 3 distribution range, price remains below down-sloping EMAs and the 50 DMA, with rallies failing into resistance and volume contracting on advances. The 3-year uptrend anchors long-term polarity, but medium-term asymmetry favors sellers. Short-term timing offers no clear edge until rallies into the 9/21 EMA zone. Execution should focus on fading strength at these EMAs around the upper boundary of the trading range.

  • ↑Phase II trials showed a 98% sustained virologic response.
  • ↑Strong $379.7M cash position sustains Phase III through 2027.
  • ↓Phase III delays or unfavorable data may stall product approval.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Atea Pharmaceuticals, Inc. (NASDAQ: ATEA) is a biopharmaceutical company primarily focused on developing innovative antiviral therapies for hepatitis infections, particularly hepatitis C virus (HCV) and hepatitis E virus (HEV). The company is currently advancing its global Phase III clinical trials that aim to disrupt the HCV treatment landscape, which is valued at approximately $3 billion annually, by providing enhanced treatment options that target significant unmet medical needs.

Bull says

  • ↑Phase II trials showed a 98% sustained virologic response.
  • ↑Strong $379.7M cash position sustains Phase III through 2027.
  • ↑Top-line C-Beyond results due mid-2026 could drive stock rallies.
  • ↑Only ~100K of 160K annual US HCV cases receive treatment.
  • ↑Regimen targets best-in-class profile with minimal drug interactions.
  • ↑Book-to-price above parity and solid institutional interest imply undervaluation.

Bear says

  • ↓Phase III delays or unfavorable data may stall product approval.
  • ↓Negative earnings yield and profitability raise concerns over returns.
  • ↓Gilead and AbbVie competition may limit market share gains.
  • ↓High R&D spend strains cash despite disciplined financial guidance.
  • ↓Volatile stock and negative momentum deter risk-averse investors.
  • ↓Weak growth, liquidity factors and large size suggest performance headwinds.

Investment themes with AVIR

Buybacks↑ +0.48%

Companies repurchasing their own shares

C · JCI · WFC

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 04-09-2026neutral

Transcript signals

Bull points

  • We are pleased to report that our cash and investments were 301.8 million at December 31, 2025.
  • In 2025, we also returned $25 million to our stockholders through a share repurchase program.
  • For 2026, we intend to maintain our rigorous financial discipline while remaining laser focused on execution and value creating advancement of our HCV and HEV product candidates.

Bear points

  • In fact, current estimates suggest we may not even achieve this goal by 2050.
  • hepatitis C is the primary cause of liver cancer in the United States, the incidence of which is projected to increase by over 50% within the next five years from approximately 850,000 cases in 2025 to 1.4 million people.
  • While EPCLUSA pricing did, net pricing did go down, which indicates pricing pressures in the market.
Read full transcript analysis ›